Labiaplasty Is the World's Fastest Growing Cosmetic Surgery Procedure, International Study Reports
An International Study Conducted by the International Society of Aesthetic Plastic Surgery Reveals Significant Growth in Labiaplasty as More Women Choose to Change the Appearance of Their Genital Area
NEW YORK, July 11, 2017 (GLOBE NEWSWIRE) -- The results of an international study recently released by the International Society of Aesthetic Plastic Surgery (ISAPS), that surveyed cosmetic procedures in 106 countries, shows significant growth in a surprising area of cosmetic surgery: labiaplasty.
Labiaplasty is a procedure that reduces the length of the labia minora, when a woman experiences discomfort from chaffing or twisting when exercising or feels self-conscious about the length of her "labia lips." In 2016, the number of labiaplasty procedures performed increased by 45%, with the top ten countries performing labiaplasty procedures as follows:
"There is a big misconception in the media and among some members of the public that labiaplasty is not a cosmetic surgery procedure, but is some kind of female genital mutilation," says Dr. Lina Triana, a Colombia-based plastic surgeon, and Board Member of ISAPS. "Unfortunately, this is a common misunderstanding, but nothing could be further from the truth. Labiaplasty is a cosmetic procedure, no different than having a breast reduction or breast augmentation, that is intended to improve the quality of life for a patient. We see many women who are in a great deal of pain - pinching and chaffing, or sores caused by excess labia skin," adds Dr. Triana. "Most female patients request Labiaplasty to help minimize pain, while others request it to improve the aesthetic appearance of their genital area. This procedure empowers women, and helps them achieve a better quality of life through increased comfort and sexual confidence. Female genital mutilation, on the other hand, is the exact opposite, repressing a woman's sexual function, as well as her confidence and her quality of life."
Dr. Renato Saltz, President of ISAPS, agrees. "As plastic surgeons, we are committed to enhancing a patient's quality of life. The significant growth of labiaplasty and vaginal rejuvenation in general [which increased by an additional 11% in 2016] shows us that more women are deciding to take action instead of living with their discomfort. We are expecting this growth to continue as more patients become aware of the procedure as an option for them."
The data on aesthetic/cosmetic surgical and non-surgical procedures performed in 2016 was tabulated with a questionnaire sent to approximately 35,000 plastic surgeons in the ISAPS proprietary database. ISAPS is the only organization that collects this type of cosmetic data annually on a global scale. The results were compiled, tabulated and analyzed by Industry Insights, an independent research firm based in Columbus, Ohio. For a copy of full results, please visit www.ISAPS.org.
The International Society of Aesthetic Plastic Surgery is the premier global organization for board certified plastic surgeons. Regarded as the leading global authority on aesthetics and cosmetic surgery, ISAPS has over 3,200 members in 104 countries. Through its rigorous membership requirements, ISAPS plastic surgeons are considered to be among the most qualified in their respective countries, making it easy for patients who are considering cosmetic surgery to start their journey by meeting with an ISAPS plastic surgeon. A full list of ISAPS plastic surgeons can be found at www.ISAPS.org.
Media Contact Julie Guest, ISAPS Chief Marketing Officer marketing@ISAPS.org 1-844-867-3621
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ISAPS via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Leading Medical Organizations Update Guideline for Molecular Testing and Targeted Therapies in Lung Cancer23.1.2018 21:11 | Pressmeddelande
DENVER, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Rapid advancements in the molecular diagnostic testing of lung cancer have led to new treatments and greater hope for patients battling lung cancer, the most common cause of cancer death worldwide. To ensure that clinicians stay apace and provide optimal patient care, three leading medical societies-the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP)-have updated their 2013 evidence-based guideline. Published today in early online release, the "Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors," continues to set standards for the molecular analysis of lung cancers for test results that effectively guide targeted therapy and treatment. Targeted cancer therapies are drugs or other treatments that block the spread of cancer by interfering with specific molec
CashBet Seeks $40 Million for World's Only Complete Crypto-Ready Mobile iGaming Platform23.1.2018 16:31 | Pressmeddelande
Gaming and cryptocurrency industry leaders develop blockchain-based iGaming platform improving trust, speed, access, costs, and content availability OAKLAND, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Leading mobile-first iGaming platform provider CashBet (https://coin.cashbet.com/) today announced it seeks to raise $40 million through an Initial Coin Offering (ICO) to develop the world's first complete crypto-ready mobile iGaming platform. Interactive gaming, which includes real money, social, skill-based, esports and sports betting, hit $91 billion in 2016, led by mobile gaming. Despite strong growth, current iGaming operations continue to face three major issues: trust, speed, and cost. CashBet is the first and only vertically integrated iGaming solution to leverage blockchain technology for transparent operations, increased speed, and lower transaction fees. The CashBet Coin will be available in pre-sale starting January 24, 2018 at 5:00 p.m. GMT, with a 20 percent discount offered.
BrandSafway Announces Acquisition of Venko Groep BV23.1.2018 16:30 | Pressmeddelande
Combined customers to benefit from broader range of services and greater depth of expertise KENNESAW, GA, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Brand Industrial Services, known as BrandSafway, has acquired Venko Groep BV, a portfolio company of Mentha Capital, effective January 1, 2018. Moving forward, the company will operate as Venko, A BrandSafway Company and become a part of Brand Energy & Infrastructure Services (Brand) in Europe. "We're excited to announce the closing of the acquisition of Venko," said Dave Witsken, President of Energy and Industrial for BrandSafway. "Venko is a leading offshore coatings maintenance provider for platforms in Europe. By leveraging the highly specialized knowledge and capabilities of Venko, we will be able to provide expanded coatings services to Brand's European customers. At the same time, with our support, Venko will now be able to offer their customers a broader inventory of access equipment and additional industrial services, such as insulation an
Data on Novel Humanized Models for Targeted Immunotherapy Development, a CrownBio Conference Talk on January 24th, 201823.1.2018 14:53 | Pressmeddelande
SAN DIEGO, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will unveil data supporting use of its cost-effective, humanized drug target models at the Tumor Models Conference in San Francisco tomorrow, Wednesday, January 24th, 2018. Humanized research tools are crucial to the development of target-specific immunotherapies like pembrolizumab and ipilimumab. To help improve research in this burgeoning field, CrownBio has developed a humanized platform that informs the preclinical pharmacology of targeted immunotherapies, including solutions for PD-1, PD-L1, OX40, and CD3E. Constituent models feature fully functional murine immunity with humanized drug targets that can be used in conjunction with syngeneic tumor cell lines engineered to expr
Music Legend Joey Fatone Will Be Celebrity Grand Marshal Of First Ever 15th Annual World's Shortest St. Patrick's Day Parade In Hot Springs, Arkansas23.1.2018 13:56 | Pressmeddelande
HOT SPRINGS NATIONAL PARK, Ark., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Music legend Joey Fatone, who soared to worldwide fame as a member of boy-band *NSYNC, will be celebrity grand marshal of the First Ever 15th Annual World's Shortest St. Patrick's Day Parade in downtown Hot Springs March 17, 2018, reports Hot Springs Convention & Visitors Bureau. He'll round out a quartet of celebrities who will be part of the quirky parade, which annually draws throngs to world-famous Bridge Street, the shortest street in the world in everyday use - 98 feet long. Jon Heder, who became famous as Napoleon Dynamite, will be the parade's official starter. The 2018 parade will begin at 7:30 p.m., an hour later than previous years. The start time was changed to allow Oaklawn racing fans plenty of time to enjoy the live racing including The Rebel Stakes at Oaklawn Park, and still get downtown for the start of the parade. Morris Day and the Time will perform a free concert at the conclusion of the parade. On F
HemCheck och Region Västmanland i studie om hemolyserade blodgasprov23.1.2018 13:30 | Pressmeddelande
PRESSMEDDELANDE HemCheck och Region Västmanland i studie om hemolyserade blodgasprov Karlstad 23 januari 2018: HemCheck Sweden AB meddelar idag att bolaget tecknat ett avtal med Region Västmanland avseende en studie för att kartlägga förekomsten av hemolys i blodgasprover tagna vid akutmottagningen på Västmanlands Sjukhus i Västerås. Blodgasanalys är ett blodprov som tas rutinmässigt på sjukhus och som är ett centralt verktyg när snabba svar krävs för kritiska diagnoser. Blodgasanalysen påverkas, liksom vanlig blodprovstagning, av hemolys, men i vilken omfattning är ännu inte lika väl dokumenterat. -Idag utförs ingen hemolyskontroll på blodgasprov. Avsikten med studien är att undersöka förekomsten av hemolys i blod som analyserats i blodgasapparater och se om det kan detekteras med hjälp av ett enkelt test. Det är glädjande att vi som ett första steg i det arbetet kan genomföra en så viktig studie ihop med Region Västmanland och Västmanlands Sjukhus Västerås. Vi ser att väl fungerande
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum